Literature DB >> 11174021

Vasopressin and diabetes mellitus.

L Bankir1, P Bardoux, M Ahloulay.   

Abstract

In diabetes mellitus (DM), the urine flow rate is increased, and the fluid turnover in the body is accelerated because of the glucose-induced osmotic diuresis. On the other hand, plasma vasopressin (VP) is elevated in both type 1 and type 2 DM. This elevation seems to be due to a resetting of the osmostat. A high VP level is beneficial in the short term because it limits to some extent the amount of water required for the excretion of a markedly enhanced load of osmoles (mainly glucose). However, in the long run, it may have adverse effects by favoring the development of diabetic nephropathy. VP has been shown in normal rats to induce kidney hypertrophy, glomerular hyperfiltration, and an increase in urinary albumin excretion (features also occurring in association in the period preceding diabetic nephropathy). Moreover, VP has been shown to participate in the progression of renal failure in rats with five-sixths reduction in renal mass. In recent studies, we have shown (1) that creatinine clearance, albuminuria and renal mass increased much less during experimental DM in Brattleboro rats unable to secrete VP than in their VP-replete Long-Evans controls, and (2) that albuminuria was prevented during experimental DM in Wistar rats when a VP nonpeptidic, highly selective V2 receptor antagonist was administered chronically for 9 weeks. Taken together, these results strongly suggest that VP plays a crucial role in the onset and aggravation of the renal complications of DM. The mechanisms by which VP exerts these adverse V2-dependent effects are not yet elucidated. They are most likely indirect and may involve several intermediate steps comprising VP-induced changes in the composition of the tubular fluid in the loop of Henle (due to solute recycling in the renal medulla associated with improved concentrating activity of the kidney), inhibition of the tubuloglomerular feedback control of glomerular function, and alterations in glomerular hemodynamics by the intrarenal renin-angiotensin system. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174021     DOI: 10.1159/000045879

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  24 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Relationship between non-osmotic arginine vasopressin secretion and hemoglobin A1c levels in adult patients with congenital heart disease.

Authors:  Tomoaki Murakami; Yoko Horibata; Shigeru Tateno; Yasutaka Kawasoe; Koichiro Niwa
Journal:  Heart Vessels       Date:  2018-11-20       Impact factor: 2.037

3.  Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

Authors:  W E Boertien; I J Riphagen; I Drion; A Alkhalaf; S J L Bakker; K H Groenier; J Struck; P E de Jong; H J G Bilo; N Kleefstra; R T Gansevoort
Journal:  Diabetologia       Date:  2013-04-28       Impact factor: 10.122

4.  Diabetes Complications in Childhood Diabetes-New Biomarkers and Technologies.

Authors:  Petter Bjornstad; David M Maahs
Journal:  Curr Pediatr Rep       Date:  2015-04-04

Review 5.  Water intake keeps type 2 diabetes away? Focus on copeptin.

Authors:  Giovanna Muscogiuri; Luigi Barrea; Giuseppe Annunziata; Martina Vecchiarini; Francesco Orio; Carolina Di Somma; Annamaria Colao; Silvia Savastano
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

6.  Enhanced coronary arteriolar contraction to vasopressin in patients with diabetes after cardiac surgery.

Authors:  Nicholas Sellke; Alex Kuczmarski; Isabella Lawandy; Victoria L Cole; Afshin Ehsan; Arun K Singh; Yuhong Liu; Frank W Sellke; Jun Feng
Journal:  J Thorac Cardiovasc Surg       Date:  2018-06-08       Impact factor: 5.209

7.  SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.

Authors:  Y Lytvyn; P Bjornstad; A Katz; S K Singh; L C Godoy; L T Chung; C L Vinovskis; L Pyle; R Roussel; B A Perkins; D Cherney
Journal:  Diabetes Metab       Date:  2019-12-06       Impact factor: 6.041

8.  Elevated copeptin, arterial stiffness, and elevated albumin excretion in adolescents with type 1 diabetes.

Authors:  Pattara Wiromrat; Petter Bjornstad; Carissa Vinovskis; Linh T Chung; Carlos Roncal; Laura Pyle; Miguel A Lanaspa; Richard J Johnson; David Z Cherney; Tyler K Reznick-Lipina; Franziska Bishop; David M Maahs; Raj Paul Wadwa
Journal:  Pediatr Diabetes       Date:  2019-08-29       Impact factor: 4.866

Review 9.  Diabetes mellitus and electrolyte disorders.

Authors:  George Liamis; Evangelos Liberopoulos; Fotios Barkas; Moses Elisaf
Journal:  World J Clin Cases       Date:  2014-10-16       Impact factor: 1.337

10.  Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats.

Authors:  Sun Shin Yi; In Koo Hwang; Yo Na Kim; Il Yong Kim; Son-Il Pak; In Se Lee; Je Kyung Seong; Yeo Sung Yoon
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.